Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown. To Delay or Not to Delay Hip Fracture Surgery

Size: px
Start display at page:

Download "Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown. To Delay or Not to Delay Hip Fracture Surgery"

Transcription

1 Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown To Delay or Not to Delay Hip Fracture Surgery

2 "You may delay, but time will not, and lost time is never found again." Benjamin Franklin

3 Reasons for Delay > 48 Hours

4 ASA Classification of Patients

5 Acceptable Reasons for Delay

6 Acceptable Reasons for Delay

7 Anaemia

8 Anaemia ~ 40% patients have anaemia Hb conc decreases 2.5g/dL perioperative period Adhere to a restrictive transfusion strategy Consider transfusion if Hb 8 g/dl or less Transfuse if symptomatic of anaemia or if patient has stable cardiovascular disease

9 Severe Electrolyte Imbalance

10 Severe Electrolyte Imbalance Hyponatraemia why should we treat it preoperatively? Increase in subsequent peri-operative complications Hypernatraemia assoc with increased mortality after surgery

11 Uncontrolled Diabetes

12 Uncontrolled Diabetes Patients who manifested a serum glucose greater than 220 mg/dl (12 mmol/l) had a 25% infection rate including: wound infections pneumonia urinary tract infections bacteraemia or severe sepsis Perioperative glucose levels greater than 220 mg/dl (12mmol/L) increased the likelihood of infection by a factor of seven in orthopaedic trauma patients even with no known history of DM

13 Uncontrolled / Acute Left Ventricular Failure An echocardiogram is indicated for anyone with: suspicious systolic murmur, dyspnoea of unknown cause worsening CCF If echo is delayed, surgery should proceed with relevant anaesthetic precautions and monitoring in place Bedside echocardiography may be useful tool to stratify surgical risk and optimize patients by assessing a patient s: intravascular volume status myocardial contractility/ventricular ejection fraction valvular heart disease in the peri-operative period Aortic Stenosis - echocardiography is indicated if it has not been performed recently

14 Correctable Cardiac Arrhythmia, Ventricular Rhythm > 120bpm

15 Correctable Cardiac Arrhythmia, Ventricular Rhythm > 120bpm Normal atrial activity accounts 10% ventricular filling up to 40% fast ventricular heart rates Elderly more dependent atrial activity due reduced elasticity ventricles Adverse effects AF more profound elderly and those underlying cardiovascular disease

16 Correctable Cardiac Arrhythmia, Ventricular Rhythm > 120bpm

17 Chest Infection With Sepsis

18 Chest Infection and Sepsis Prevalence preoperative pneumonia 1.2% Independent risk factor mortality and adverse events Underweight BMI assoc w higher mortality within 30 days Time from admission to surgery not assoc adverse events

19 Reversible Coagulopathy Drug Class Drug Name SAB Surgery Anti-platelet Clopidogrel (Plavix) Not recommended within 7 days of taking last dose of 75mg/day of clopidogrel. Low Molecular Weight Heparin Enoxaparin (Clexane) Avoid SAB if prophylactic dose administered within the last 12 hours. 1 & 4 Avoid SAB if therapeutic dose administered within the previous 24 hours. 1 & 4 Note these intervals are extended in renal impairment. If surgery is required within 48 hours of last dose it is suggested that platelets (2 pools) be ordered and in the hospital prior to surgery Unfractionated Heparin Heparin infusion Cease infusion 4 hours before surgery

20 Reversible Coagulopathy Drug Class Drug Name SAB Surgery Coumadins Warfarin INR should be 1.3 prior to placement of SAB Direct Thrombin Inhibitors Dabigatran (Pradaxa) 2 4 days after last dose depending on creatinine clearance INR normally takes 5 days to return to normal after cessation of warfarin. INR < 2. If surgery is required before this, emergency reversal of warfarin can be performed. 2 4 days after last dose depending on creatinine clearance * Can reverse with idarucizumab Factor Xa Inhibitors Rivaroxaban (Xarelto) Avoid SAB for three days after last dose taken Proceed with Sx 48 hours after last dose taken Apixaban (Eliquis) Avoid SAB for three days after last dose taken Proceed with Sx 48 hours after last dose of taken

21 Conclusions Delays due to medical optimisation of patients could be improved AAGBI clear guidelines on appropriate delays surgery NOACs problematic cause delays until cost effective antidotes

Dr Ben Edwards Consultant Anaesthetist Sheffield Teaching Hospitals

Dr Ben Edwards Consultant Anaesthetist Sheffield Teaching Hospitals Dr Ben Edwards Consultant Anaesthetist Sheffield Teaching Hospitals 70-75,000 #NOF per annum (costs 2 billion) 10% die within 1 month 33% die within 1 year Operative delays >48hs more than doubles risk

More information

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran. Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct

More information

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an

More information

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the

More information

Anticoagulation Task Force

Anticoagulation Task Force Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration

More information

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity

More information

KCS Congress: Impact through collaboration

KCS Congress: Impact through collaboration Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact

More information

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

GWTG Post-Discharge Follow-up Form

GWTG Post-Discharge Follow-up Form Bold font = Required field Patient ID: Date of Hospital Admission: / / mm / dd / yyyy Date Follow-up Completed: / / mm / dd / yyyy PATIENT LOGISTICS Method used for Patient follow-up: Chart Review Health

More information

The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.

The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F. The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation

More information

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS

Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with

More information

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant

More information

What s new with DOACs? Defining place in therapy for edoxaban &

What s new with DOACs? Defining place in therapy for edoxaban & What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor

More information

Clinical Practice Guideline for Anticoagulation Management

Clinical Practice Guideline for Anticoagulation Management Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.

More information

Novel Anticoagulants: Emerging Evidence

Novel Anticoagulants: Emerging Evidence 18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant

More information

Managing Perioperative Anticoagulation. Edie Shen MD

Managing Perioperative Anticoagulation. Edie Shen MD Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)

More information

Comparison of novel oral anticoagulants (NOACs)

Comparison of novel oral anticoagulants (NOACs) Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic

More information

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from

More information

Oral Anticoagulation Drug Class Prior Authorization Protocol

Oral Anticoagulation Drug Class Prior Authorization Protocol Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Professional Practice Minutes December 7, 2016

Professional Practice Minutes December 7, 2016 Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon

More information

Is Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?

Is Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Apixaban Effective for the Prevention

More information

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

Anaesthesia. Clinical overview articles. Update in. Neck of femur fracture: perioperative management. Ronald Cheung

Anaesthesia. Clinical overview articles. Update in. Neck of femur fracture: perioperative management. Ronald Cheung Neck of femur fracture: perioperative management Ronald Cheung Correspondence: roncheung39@gmail.com Originally published as Anaesthesia Tutorial of the Week 296, 21 October 2013 INTRODUCTION Several large

More information

Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.

Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose. Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic

More information

Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016

Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with

More information

Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian. Barry McKenzie, MD St. Vincent Healthcare

Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian. Barry McKenzie, MD St. Vincent Healthcare Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian Barry McKenzie, MD St. Vincent Healthcare Objectives Describe the increasing frequency of trauma patients being

More information

Intrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway

Intrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway Anticoagulant Cases 12 11 Intrinsic + Common = aptt 9 8 10 7 4 Extrinsic + Common = PT 5 2 Common Pathway 1 Xa Inhibitors rivaroxaban (Xarelto) apixaban (Eliquis) edoxaban (Savaysa) What is true regarding

More information

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor

More information

Atrial fibrillation: current approaches to management

Atrial fibrillation: current approaches to management DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an

More information

New Age Anticoagulants: Bleeding Considerations

New Age Anticoagulants: Bleeding Considerations Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University

More information

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe

More information

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

Analysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb. Tro Kalayjian Chief Medical Analyst Chimera Research Group

Analysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb. Tro Kalayjian Chief Medical Analyst Chimera Research Group Analysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb Tro Kalayjian Chief Medical Analyst Chimera Research Group Prevalence of AFib in the US is expected to increase upwards of

More information

New Anticoagulants Therapies

New Anticoagulants Therapies New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations

More information

Treatment Options and How They Work

Treatment Options and How They Work Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the

More information

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get

More information

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical

More information

Dr Calum Young Cardiologist Tauranga

Dr Calum Young Cardiologist Tauranga Dr Calum Young Cardiologist Tauranga 8:30-9:25 WS #93: New Oral Anticoagulant Drugs and Management of AF 9:35-10:30 WS #105: New Oral Anticoagulant Drugs and Management of AF (Repeated) GPCME 2016: Anticoagulation

More information

Venothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2

Venothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2 Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin

More information

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade

More information

Direct Oral Anticoagulants An Update

Direct Oral Anticoagulants An Update Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

Coagulation, Haemostasis and interpretation of Coagulation tests

Coagulation, Haemostasis and interpretation of Coagulation tests Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect

More information

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:

More information

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation

More information

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review

More information

Updates in Atrial Fibrillation

Updates in Atrial Fibrillation Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000

More information

Advances in Anticoagulation

Advances in Anticoagulation May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on

More information

Reducing the Use of Reversal Agents in a Community Hospital

Reducing the Use of Reversal Agents in a Community Hospital 4//0 Objectives Reducing the Use of Reversal Agents in a Community Hospital Maria Paulina Duarte, PharmD PGY- Pharmacy Resident Mercy Hospital, A Campus of Plantation General Hospital Review the appropriate

More information

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow

More information

Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio

Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss

More information

Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents

Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist

More information

PRACTICAL MANAGEMENT OF NOAC s December 8,

PRACTICAL MANAGEMENT OF NOAC s December 8, PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:

More information

Atrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation

Atrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation The (S)Low-down on Rapid Afib Resuscitation 2017 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN Atrial Fibrillation

More information

PREOPERATIVE PATIENT PREPARATION PROTOCOL

PREOPERATIVE PATIENT PREPARATION PROTOCOL PREOPERATIVE PATIENT PREPARATION PROTOCOL Each surgical discipline should have a standard set of published guidelines for the preparation of its patients for theatre procedures. These should be readily

More information

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Appendix C Factors to consider when choosing between anticoagulant options and FAQs Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened

More information

Multidisciplinary Geriatric Trauma Care Guideline

Multidisciplinary Geriatric Trauma Care Guideline Multidisciplinary Geriatric Trauma Care Background Traumatic injury in the geriatric population is increasing in prevalence and is associated with higher mortality and complication rates comparted to younger

More information

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients

More information

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately

More information

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular

More information

CARDIOLOGY. Certification Updates with Clinical Aspects. Federal Aviation Administration

CARDIOLOGY. Certification Updates with Clinical Aspects. Federal Aviation Administration CARDIOLOGY Certification Updates with Clinical Aspects Presented to: 2017 By: John S. Raniolo, D.O. Date: September 14, 2017 2 2012 Roundtable discussion (OKC, AAM 100 & 200) reviewed the current FAA cardiology

More information

NOACS/DOACS*: COAGULATION TESTS

NOACS/DOACS*: COAGULATION TESTS NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international

More information

Challenges in Coagulation

Challenges in Coagulation Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from

More information

Haematology Subcommittee of PTAC Meeting held 16 March 2016

Haematology Subcommittee of PTAC Meeting held 16 March 2016 Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Cost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib

Cost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million

More information

Anticoagulants: Agents, Pharmacology and Reversal

Anticoagulants: Agents, Pharmacology and Reversal Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University

More information

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management

More information

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)

More information

Aims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies

Aims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each

More information

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest.

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest. Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all

More information

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or

More information

a. A pharmacist may order a baseline SCr per protocol

a. A pharmacist may order a baseline SCr per protocol UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin

More information

Role and impact of orthogeriatric service in the hip fracture care pathway: 15-year experience

Role and impact of orthogeriatric service in the hip fracture care pathway: 15-year experience Role and impact of orthogeriatric service in the hip fracture care pathway: 15-year experience AA Fisher, MW Davis Department of Geriatric Medicine, The Canberra Hospital, and Australian National University

More information

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications

More information

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October

More information

Patient Encounters in the Primary Care Setting

Patient Encounters in the Primary Care Setting Patient Encounters in the Primary Care Setting Carmine D Amico, D.O. Clinical Cases Overview Learning objectives Clinical case presentations Questions for audience participation 1 Clinical Cases Learning

More information

ADMINISTRATIVE CLINICAL Page 1 of 6

ADMINISTRATIVE CLINICAL Page 1 of 6 ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15

More information

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI 10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:

More information

Nanik Hatsakorzian Pharm.D/MPH

Nanik Hatsakorzian Pharm.D/MPH Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

Reversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding

Reversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)

More information

Heart Valves: Before and after surgery

Heart Valves: Before and after surgery Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and

More information

EACTS Adult Cardiac Database

EACTS Adult Cardiac Database EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list

More information

Bios 6648: Design & conduct of clinical research

Bios 6648: Design & conduct of clinical research Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment

More information